Metformin: Mode of action and effects in mono- and combination therapy on glucose metabolism in type 2 diabetes;Metformin: Virkningsmekanisme og effekt i mono- og kombinationsterapi på glukosestofskiftet ved type 2-diabetes

Ugeskrift for Laeger

Volumn 164, Issue 15, 2002, Pages 2025-2028

  Christiansen, Allan Lindskov ^a   Madsbad, Sten ^a  

^a NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; INSULIN; ISOPHANE INSULIN; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; THIAZOLE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; GLUCOSE METABOLISM; HUMAN; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; BLOOD; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; METABOLISM; REVIEW; TREATMENT OUTCOME;

ACARBOSE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; THIAZOLES; TREATMENT OUTCOME;

EID: 0037041857     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Metformin: A review of its metabolic effects
2. A risk-benefit assessment of metformin in type 2 diabetes mellitus
3. Lactic acidosis in patients with diabetes treated with metformin
4. Metforminassosiert laktatacidose - Pasienteksempel og litteraturgjennomgang
5. Effects of metformin on the pathways of glucose utilization after oral glucose in non-insulin-dependent diabetes mellitus patients
6. Metabolic effects of metformin on glucose and lactate metabolism in NIDDM
7. Mechanism by which metformin reduces glucose production i type 2 diabetes
8. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients
9. Acute antihyperglycemic mechanisms of metformin in NIDDM: Evidence for suppression of lipid oxidation and hepatic glucose production
10. Efficacy of metformin in type II diabetes: Results of a double-blind placebo-controlled, dose-response trial
11. Efficacy of metformin in NIDDM patients poorly controlled on diet alone or diet plus sulfonylurea
12. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM
13. Metabolic effects of metformin in non-insulin dependent diabetes mellitus
14. United Kingdom Prospective Diabetes Study 17: A 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus
15. Worldwide experience of metformin as an effective glucose-lowering agent: A meta-analysis
16. UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes
17. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
18. Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: A population-based observational study
19. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: A multicenter controlled clinical trial
20. Insulin therapy for normalizing glycosylated hemoglobin in type II diabetes: Application, benefits, and risks
21. Insulin resistance and atherosclerosis
22. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus
23. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus
24. Metformin for obese, insulin-treated diabetic patients: Improvement in glycaemic control and reduction of metabolic risk factors
25. Advantages of adding metformin to multiple dose insulin therapy in type 2 diabetes
26. The effects of metformin in poorly controlled insulin-treated type 2 diabetes mellitus
27. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control
28. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
29. Background and recruitment data for the U.S. Diabetes Prevention Program